ID   Hepa 1-6/10R
AC   CVCL_A5BH
SY   Hepa 1-6/R
DR   Wikidata; Q107115330
RX   PubMed=11004682;
RX   PubMed=12606785;
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
CC   Breed/subspecies: C57L.
DI   NCIt; C38756; Hepatocellular carcinoma of the mouse
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_0327 ! Hepa 1-6
SX   Female
CA   Cancer cell line
DT   Created: 20-05-21; Last updated: 29-06-23; Version: 4
//
RX   PubMed=11004682; DOI=10.1002/1097-0215(20001015)88:2<287::AID-IJC22>3.0.CO;2-U;
RA   Briz O., Serrano M.A., Macias R.I.R., Marin J.J.G.;
RT   "Overcoming cisplatin resistance in vitro by a free and
RT   liposome-encapsulated bile acid derivative: BAMET-R2.";
RL   Int. J. Cancer 88:287-292(2000).
//
RX   PubMed=12606785; DOI=10.1124/mol.63.3.742;
RA   Briz O., Macias R.I.R., Vallejo M., Silva A., Serrano M.A.,
RA   Marin J.J.G.;
RT   "Usefulness of liposomes loaded with cytostatic bile acid derivatives
RT   to circumvent chemotherapy resistance of enterohepatic tumors.";
RL   Mol. Pharmacol. 63:742-750(2003).
//